Indian pharmaceutical stocks staged a broad-based rally on April 23, with the Nifty Pharma index gaining 2.5% intraday, supported by improving growth trends and supportive macro tailwinds. The upmove reflects a combination of strong domestic demand, export-led earnings leverage, and renewed investor interest in specialty therapies.

According to brokerage inputs cited in a Reuters report, the Indian pharmaceutical market expanded 10.1% year-on-year in March, maintaining a double-digit growth trajectory. Importantly, several companies under coverage outperformed expectations, indicating that demand recovery is not only steady but also broad-based across therapy segments.

Market action mirrored this optimism. Shares of Dr Reddy's Laboratories surged nearly 10%, emerging as the top gainer on the index. Piramal Pharma followed with a 6.5% rise, while Cipla advanced 5.5%. Mid-tier players such as Mankind Pharma, Laurus Labs, and Glenmark Pharmaceuticals also recorded gains between 2% and 3%, indicating participation beyond large-cap names.

A key trigger for the rally in Dr Reddy’s was the growing buzz around semaglutide, a high-value molecule used in blockbuster weight-loss and diabetes drugs such as Wegovy and Ozempic, both developed by Novo Nordisk. Reports suggest potential regulatory developments in Canada, which could open incremental export opportunities.

However, as per coverage from CNBC TV18, approval for semaglutide in India is still pending, highlighting a gap between global opportunity and domestic execution.

Beyond product-specific triggers, macroeconomic factors are also playing a significant role. Brokerage Elara Securities highlighted that the depreciation of the Indian rupee over the past few months has materially improved earnings visibility for export-oriented pharmaceutical companies. Given that a large share of sector revenues is derived from overseas markets or foreign subsidiaries, currency weakness directly boosts reported revenues and margins in rupee terms.

Elara estimates suggest that rupee depreciation could have up to a 5% positive impact on FY27 revenues and as much as a 15% upside on EBITDA for companies with significant global exposure. Firms such as Zydus Lifesciences and Granules India were identified as key beneficiaries within its coverage universe.

This combination of domestic growth and currency tailwinds is particularly important at a time when global generic pricing pressures and regulatory scrutiny remain persistent concerns. The current environment suggests a partial offset to these structural headwinds.

From an Indian market perspective, the pharma sector’s performance is significant for two reasons. First, it provides a defensive growth avenue amid broader market volatility, especially when global uncertainties impact cyclical sectors. Second, the increasing focus on complex generics and specialty drugs like semaglutide indicates a gradual shift up the value chain, which could improve long-term return ratios for leading players.

Sectorally, the rally reinforces the strength of export-driven industries in a weakening currency environment. Healthcare and pharmaceuticals, alongside IT services, are among the key beneficiaries of such macro trends. Within pharma, companies with diversified geographic exposure and strong regulatory track records are likely to outperform.

However, the outlook is not without risks. Regulatory approvals, especially in highly scrutinised markets like the US and Europe, remain a key variable. Delays or adverse observations can quickly impact revenue pipelines. Additionally, while currency depreciation is currently supportive, any sharp reversal could compress margins, particularly for companies with high import dependence on active pharmaceutical ingredients.

The semaglutide opportunity, while promising, also carries execution risks. Entry into this segment requires not only regulatory clearance but also manufacturing scale and competitive pricing, given the dominance of established global players.